Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.

@article{Jazirehi2005RituximabA,
  title={Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-\{kappa\}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.},
  author={Ali R. Jazirehi and Sara Huerta-Y{\'e}pez and Genhong Cheng and Benjamin Bonavida},
  journal={Cancer research},
  year={2005},
  volume={65 1},
  pages={264-76}
}
The chimeric anti-CD20 antibody rituximab (Rituxan, IDEC-C2B8) is widely used in the clinical treatment of patients with non-Hodgkin's lymphoma (NHL). Rituximab sensitizes NHL B-cell lines to drug-induced apoptosis via down-regulation of Bcl-x(L) expression. We hypothesized that the mechanism by which rituximab down-regulates Bcl-x(L) may be, in part, due to inhibition of constitutive nuclear factor-kappaB (NF-kappaB) activity that regulates Bcl-x(L) expression. This hypothesis was tested in… CONTINUE READING